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Intracerebral hemorrhages (ICH) represent about 10–15% of all strokes per year in the
United States alone. Key variables influencing the long-term outcome after ICH are
hematoma size and growth. Although death may occur at the time of the hemorrhage,
delayed neurologic deterioration frequently occurs with hematoma growth and neuronal
injury of the surrounding tissue. Perihematoma edema has also been implicated as a
contributing factor for delayed neurologic deterioration after ICH. Cerebral edema results
from both blood–brain barrier disruption and local generation of osmotically active
substances. Inflammatory cellular mediators, activation of the complement, by-products
of coagulation and hemolysis such as thrombin and fibrin, and hemoglobin enter the brain
and induce a local and systemic inflammatory reaction. These complex cascades lead to
apoptosis or neuronal injury. By identifying the major modulators of cerebral edema after
ICH, a therapeutic target to counter degenerative events may be forthcoming.
Keywords: hypothermia, induced, neurosciences, brain edema, intracranial hypertension

INTRODUCTION
Intracerebral hemorrhage (ICH) comprises 10–15% of strokes annually in the United States and
associated with the highest morbidity and mortality (1). There is approximately 40% mortality
at 1-month postbleed, and only about 20% of those patients regain functional independence (2).
A key factor affecting ICH outcome is hematoma size and hematoma expansion. Although death
may occur acutely at the sentinel ICH event, delayed neurologic deterioration often occurs with
the evolution of the hematoma and injury of the surrounding tissue. Key variables influencing the
long-term outcome after ICH are hematoma size and location and are not modifiable at the onset
of symptoms. Hematoma growth can also be a predictor of poor outcome, and recent clinical
evidence suggests that it may be preventable. Additional risk factors for hematoma growth include
antithrombotic therapy, hypertension, large initial hematoma size, and genetic predisposition such
as with APOE genotype. Approximately 30% of patients demonstrate significant hematoma expansion during hospitalization (3). Therapies aimed at the prevention of hematoma growth generally
target either blood pressure (BP) control or hemostasis. Recent large clinical trials tested therapies
aimed at modifying these outcomes and included BP reduction and hemostatic therapy with
recombinant factor VIIa (rFVIIa) assisted by computed tomography (CT) angiography (CT-A)
findings (4).
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Perihematoma edema (PHE) has also been implicated as a
contributing factor for delayed neurologic deterioration after
ICH (5). Cerebral edema forms within hours in the immediate
vicinity of the clot (PHE) and can last for several weeks. PHE is
the result of both blood–brain barrier (BBB) disruption and local
generation of osmotically active substances that spread to adjacent structures (6). Inflammatory cellular mediators, activation of
the complement, by-products of coagulation and hemolysis such
as thrombin and fibrin, and hemoglobin spread into the brain tissue and induce a local and systemic inflammatory response. This
process likely results from complex chemotactic signals including
upregulation of adhesion molecules leading to leukocyte recruitment and migration into the brain tissue (7) (Table 1).

increased local tissue pressure leading to mechanical injury, (b)
a local fibrinolytic effect, (c) plasma protease induction, and (d)
secondary inflammation related to clotting proteins and endblood products. However, the relative importance of these factors
in the early hours after ICH is unclear (6, 19–21).
A proposed theory is that the increase in local tissue pressure
occurs in the brain surrounding the hematoma at the expense of
a form of “congestive” tissue ischemia. This phenomenon may
be similar to what is seen after cerebral infarction from cortical
vein or dural sinus thrombosis. All of these mechanisms coupled
with regional mechanical and ischemic tissue damage and the
possibility of a local coagulopathic environment may contribute
to worsening secondary bleeding from venules and arterioles.

HEMATOMA GROWTH

Clinical and Radiological Evidence in
Support of Early Hematoma Growth

Studies from ICH models that used histopathology, CT analysis,
single-photon emission computed tomography (SPECT), and
both conventional CT and CT-A techniques suggested that secondary multifocal bleeding into the perihematoma region is more
likely to occur in individuals who experience early hematoma
growth. Preliminary histopathological studies provide evidence
that the presence of microscopic and macroscopic bleeds in the
area surrounding hematoma may represent ruptured arterioles
or venules (8). More recent studies that used CT and SPECT
techniques have shown that in some patients, early hematoma
growth is associated with secondary bleeding in the periphery of
the existing hematoma and into congested areas of the perihematoma tissue (9).
Irregular clot morphology, which may represent ongoing or
active bleeding after ICH, is another variable that has been associated with (10) early hematoma growth. In support, additional
secondary studies from large randomized clinical trials on BP
reduction after ICH have also demonstrated that irregular clot
morphology is associated with worse long-term outcomes after
ICH (11). One study using CT-A technology demonstrated that
the presence of active contrast extravasation into the hematoma
was associated with subsequent hematoma growth (12) and higher
mortality (13) in 30–46% of patients (14, 15). Simultaneous bleeding from multiple lenticulostriate arteries has been demonstrated
angiographically immediately after ICH (16, 17). This evidence
suggests that early hematoma growth occurs because of bleeding
into a congested layer of tissue that forms acutely at the periphery
of the hematoma (18). Possible contributing factors include (a)

Early hematoma growth evidenced by consecutive CT scans can
occur in 18–38% of patients scanned within 3 h of ICH onset.
Multiple CT-based studies have provided further support for the
occurrence of early hematoma growth after ICH (10, 22–26). The
highest incidence of early hematoma growth (38%) was seen in
the Brott and Broderick’s study, but the investigators concluded
that the true frequency of hematoma growth may have been
higher because clinical deterioration and immediate surgical
intervention precluded the performance of the follow-up CT
scans in some of the studied patients (26). To summarize, the only
consistently identified predictor of early hematoma growth is the
time from the onset of ICH to CT scan, in other words, the earlier
the first CT scan is done, the more likely subsequent bleeding will
be detected on a follow-up CT scan (10, 25, 27).
To this end, hematoma expansion occurs in only 5% of patients
who are initially scanned beyond 6 h of symptom onset (10, 25,
26, 28). Early hematoma expansion is consistently associated
with poor clinical outcomes and higher mortality rates versus
no expansion. Similarly, significantly greater reductions in the
Glasgow Coma Scale and National Institute of Health Stroke
Scales have been reported among patients with documented
hematoma expansion on 1-h follow-up CT scans versus those
without growth (26). These observations suggest that the reduction in hematoma growth may be an important strategy for
improvement of survival and outcome after ICH.

TREATMENT STRATEGIES TO PREVENT
HEMATOMA GROWTH
BP Control

TABLE 1 | Phases of ICH and proposed pathophysiologic events [with
permission from Rincon and Mayer (59)].
Phase

Event

Time

Implicated mechanism

I

Vascular rupture

1–10 s

II

Hematoma formation

<1 h

III

Hematoma expansion

1–6 h

IV

Edema formation

24–72 h

Chronic vascular changes:
lipohyalinosis, amyloid angiopathy,
hypocholesterolemia
Blood pressure, coagulation
abnormalities
Blood pressure, perihematomal
vascular + tissue injury
Cellular and humoral toxicity,
blood degradation products
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Patients with ICH should have tightly managed BP, but it
is frequently elevated acutely (29). In the majority of cases,
extremely high admission BP is the primary therapeutic issue in
ICH patients. In the Study of Treatment of Acute Hypertension
(30), nearly 30% of patients who presented to an Emergency
Department with acute hypertension had a demonstrable
brain injury of which 30% were ICHs. Systolic blood pressure
(SBP > 140 mmHg) is seen in >75% of patients with ICH (29,
31). Causes of this hypertensive response include upregulation of
the sympathetic nervous system and the renin–angiotensin and
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pituitary-adrenal axis (32). Single-center studies and a systematic
review have independently demonstrated a higher risk of early
clinical deterioration, mortality, and worst long-term outcome
with either extreme high or low levels of BP after ICH (33–38).
Extreme levels of BP could theoretically contribute to acute
hematoma growth and later aggravate PHE and intracranial
pressure (ICP). This could potentially translate into worst shortand long-term outcomes after ICH (39, 40). Preliminary studies
provided some evidence of early hematoma growth from bleeding into an ischemic penumbra zone surrounding the hematoma
(41, 42). However, other studies did not confirm the existence
of such ischemic and hypoperfused area in the periphery of the
hematoma. In the landmark study by Brott et al. (26), acute hypertension after ICH was not associated with hematoma growth, but
the authors suggested that the use of antihypertensive agents
may have negatively confounded this association. Similarly, acute
hypertension was not associated with hematoma growth in the
Recombinant Activated Factor VII ICH Trial (43).
Despite this conflicting evidence, the overall consensus is
that extreme levels of BP (either low or high) after ICH should
be treated carefully. Controversy exists regarding the optimal
threshold for treatment and target level [SBP versus mean arterial pressure (MAP)]. Aggressive BP reduction in the setting
of impaired autoregulation may predispose to perihematomal
or distant brain tissue ischemia, whereas intact autoregulation
might result in reflex vasodilation and increase in cerebral
edema resulting in higher ICP (44, 45). In a small pilot study
of BP reduction after ICH, 14 patients with supratentorial ICH
were randomized to receive either labetalol or nicardipine within
22 h of ictus with the aim to lower the MAP by 15%. Cerebral
blood flow (CBF) studies were performed before and after treatment with positron emission tomography and [15O] water. No
changes in global or perihematoma CBF were observed (46).
Finally, earlier studies also demonstrated that a controlled pharmacologically based reduction in BP had no adverse effects on
CBF in both humans and animals (47, 48). These preliminary
evidence led to the development of clinical studies on aggressive
BP control after ICH.
Seven clinical trials have evaluated the role of intensive BP
reduction after ICH (49–55). The Intensive Blood Pressure
Reduction in Acute Cerebral Hemorrhage Trial (INTERACT)-I
phase II study was an open-label trial of 403 patients randomized to
a target SBP of <180 (guideline recommendation) or <140 mmHg
within 6 h of onset (56). The study showed a trend toward lower
relative and absolute hematoma growth from baseline to 24 h
in the intensive treatment group (SBP < 140 mmHg) compared
with the control group. The phase III clinical trial INTERACT-II

concluded that aggressive BP control did not result in a significant
reduction in the mortality rate or severe disability after ICH (54,
57). However, a trend was observed when the primary outcome
was analyzed in an ordinal fashion, suggesting that in a selected
cohort of ICH patients, intensive lowering of BP may improve
long-term outcomes (57).
The Antihypertensive Treatment in Acute Cerebral
Hemorrhage (ATACH)-I trial (52, 58) confirmed the feasibility
and safety of early rapid BP reduction in ICH. This phase II
randomized prospective controlled study employed a dose escalation regimen of intravenous nicardipine for BP reduction in 80
patients with ICH. No effect was seen on outcome or neurological worsening. Both INTERACT-II and ATACH-I showed that
although early and intensive BP lowering is clinically feasible and
safe, this was not associated with meaningful clinical outcome
differences (see Table 2).
The recently completed phase III ATACH-II clinical study
was closed based on futility translating into no meaningful
benefit from the intensive treatment group (SBP < 140 mmHg)
compared to the guideline recommendation (SBP < 180 mmHg)
(53). The ATACH-II trial was designed to evaluate the efficacy of
aggressively lowering the SBP in ICH patients but in an earlier
time-window (60). One aim of the ATACH-II trial was to show
that a more rapid intensive reduction in the SBP level than that
used in INTERACT-II would make it more likely to show a larger
therapeutic benefit. However, the intensive and early treatment
did not result in a lower rate of mortality or poor outcome.
In the Intracerebral Hemorrhage Acutely Decreasing
Arterial Pressure Trial (ICH-ADAPT) I (55), the use of a strict
triple-regimen BP lowering protocol permitted a significant
BP difference between the groups at 2 h postrandomization. The target BP was achieved in 79% of patients in the
<150 mmHg group at 2 h. The follow-up phase II ICH-ADAPT
II is designed to test the hypothesis that aggressive antihypertensive therapy will alter the natural history of hematoma
growth, improving outcomes after ICH using MRI and DWI
as primary outcomes. The study will identify biomarkers that
may be putative mediators of ischemic injury in ICH patients
(49) (see Table 3).
Current recommendations for Guidelines for the Management
of Spontaneous Intracerebral Hemorrhage from AHA/ASA state
that for “ICH patients presenting with SBP between 150 and
220 mmHg and without contraindication to acute BP treatment, acute lowering of SBP to 140 mmHg is safe (Class I; Level
of Evidence A) and can be effective for improving functional
outcome (Class IIA; Level of Evidence B)” (61). This recommendation is consistent with the results of the ATACH-II trial

TABLE 2 | Comparison of INTERACT-II versus ATACH-II trials.
Randomization

Treatment group

Control group

Outcome

INTERACT-II

All within 6 h of symptom onset;
48% systolic blood pressure
(SBP) > 180 mmHg

Target SBP < 180 mmHg within 1 h
after randomization

Target SBP < 140 mmHg with agents of
physician’s choosing

No significant reduction in
modified Rankin Scale (mRS)
score at 3 months

ATACH-II

All within 4.5 h of symptom onset;
SBP > 180 mmHg

Maintain SBP 140–179 mmHg
during 24 h after randomization

Maintain SBP 110–139 mmHg during 24 h
after randomization with first-line nicardipine
and second-line labetalol

No significant reduction in mRS
score at 3 months

Frontiers in Neurology | www.frontiersin.org
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TABLE 3 | Prospective clinical trials of blood pressure management in ICH.
Trial

Study design

SBP targets

Onset to randomization
time

Medical intervention used

End point

INTERACT

n = 404, RCT, PROBE, phase II

Standard: <180
Intensive: <140

<6 h

Variable

24 h hematoma growth

INTERACT-II

n = 2,839, RCT, phase III

Standard: <180
Intensive: <140

<6 h

Variable

mRs at 90 days

ATACH

n = 60, RCT, phase II

Tier 1: <170–200
Tier 2: <140–170
Tier 3: <110–140

<6 h

Nicardipine

Treatment feasibility and safety

ATACH-II

n = 1,200, RCT, PROBE, phase III

Standard: <180
Intensive: <140

<4.5 h

Nicardipine

mRS at 90 days

ICH ADAPT

n = 75, RCT, PROBE, phase II

Standard: <180
Intensive: <150

<24 h

Labetalol
Hydralazine
Enalapril

Perihematoma CBF

ICH ADAPT II

RCT, PROBE, phase II

Standard: <180
Intensive: <140

<6 h

Labetalol
Hydralazine
Enalapril

DWI lesion frequency at 24 h

RCT, randomized control trial; PROBE, prospective randomized open blinded end point; CBF, cerebral blood flow; mRS, modified Rankin Scale; SBP, systolic blood pressure.

in which participants with intracerebral hemorrhage volume
<60 cm3 and participants with intracerebral hemorrhage volume
<60 cm3 and GCS > 5 were assigned to a SBP goal <140 mmHg
or SBP < 180 mmHg. The ATACH-II trial did not result in a
lower rate of death or disability with acute reduction of SBP to
goal <140 mmHg than the standard goal SBP < 180 mmHg. The
absolute difference between the two groups in the rate of death or
disability was 1 percentage point (60). Although feasible and safe,
the rate of renal adverse events within 7 days after randomization
in ATACH-II was significantly higher in the intensive treatment
group than in the standard-treatment group (9.0 versus 4.0%,
P = 0.002) (60).

routine use of rFVIIa as a hemostatic therapy for patients with
spontaneous ICH cannot be recommended. A post hoc study
of the FAST clinical trial demonstrated that factor rFVIIa may
be useful in younger patients who present within an earlier
time-window, but further recommendations may need to be
supported by future clinical trials (64).
A preliminary clinical study of the antifibrinolytic agent
epsilon aminocaproic acid (ECA) was conducted with negative results (65). The management of ICH with Aminocaproic
acid open-label pilot study (MANICHAN-PILOT) and the
Antifibrinolytic Therapy in Acute Intracerebral Hemorrhage
clinical trial are also designed to test the hypothesis that ECA
administration within 3 h of ICH is associated with less hematoma growth and improved outcomes (66, 67). As antifibrinolytic therapies carry a higher risk of adverse thromboembolic
events, additional studies have focused on determining the
specific population of patients that might benefit from this
therapy. Four ongoing clinical trials are studying if imageassisted antifibrinolytic therapy may offer further benefit by
identifying ICH patients with ongoing bleeding and whom may
benefit from acute hemostasis (68–71).
Although CT-A post-ICH is not routinely performed in all
clinical centers, it may prove helpful in predicting hematoma
growth and clinical outcomes (13, 72). In a prospective study of
39 patients with spontaneous ICH, focal enhancing foci (contrast
extravasation, “spot sign”) seen in initial CT-A was associated
with the presence and extent of hematoma progression with good
sensitivity (91%) and negative predictive value (96%) (14). In
the “Spot Sign” Selection of Intracerebral Hemorrhage to Guide
Hemostatic Therapy (SPOTLIGHT), ICH patients with a “spot
sign” (14) will be randomly assigned to a single injection of rFVII
or placebo. The study aims at evaluating the rate of hematoma
growth and the difference in proportion of clinical outcomes
such as death and disability (69). In the Spot Sign for Predicting
and Treating ICH Growth Study (STOP-IT), investigators will

Hemostasis

As hematoma growth is a powerful predictor of outcome after
spontaneous ICH, it makes biological sense to attempt to
optimize hemostasis as early as possible. rFVIIa (Novoseven®,
Novo Nordisk) has been approved for the management of
bleeding patients with congenital forms of hemophilia and who
are resistant to conventional factor VIII replacement therapy.
There is substantial evidence that rFVIIa may optimize hemostasis in patients with normal coagulation function. Recently, a
randomized controlled phase II study of 399 patients with spontaneous ICH demonstrated that the administration of rFVIIa
at doses of 40, 80, or 160 µg/kg within 4 h of onset was associated with a 38% reduction in death and improved functional
outcomes at 90 days, despite a 5% increase in the frequency
of arterial thromboembolic adverse events (62). However, this
effect was not replicated in the follow-up phase III FAST clinical
trial of rFVIIa after ICH. In this study, doses of 80 and 20 µg/kg
of rFVIIa were compared against placebo in 841 subjects with
spontaneous ICH. The study found no significant difference in
the proportion of patients with death or severe disability (mRS
5–6) at 90 days, but the hemostatic effect and adverse effect
profiles were replicated (63). On the basis of these results, the

Frontiers in Neurology | www.frontiersin.org
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determine whether CT-A can predict which individuals with ICH
will experience significant hematoma growth in the size of the
hemorrhage and the effect of rFVIIa on hematoma growth (68).
The end points of the Tranexamic Acid for Acute ICH Growth
prEdicted by Spot Sign (TRAIGE) clinical trial and the Spot Sign
and Tranexamic Acid On Preventing ICH Growth—AUStralasia
Trial (STOP-AUST) are similar to STOP-IT, but in this study, the
investigators will use tranexamic acid, a newer antifibrinolytic
agent (70, 71).
Additional studies related to hemostasis involve the use
of platelet transfusions and prothrombin complex concentrate (PCCs) for coagulopathic or antiplatelet-exposed ICH
patients and optimization of coagulation before neurosurgical
interventions (73–76). One study recently assessed the effect
of platelet transfusion in an open-label inception cohort of
ICH patients who underwent platelet function assays with
Accumetrics (75). In those patients with abnormal platelet
function results and risk of poorer outcome, early platelet
transfusion improved platelet activity and was associated with
smaller hematoma sizes and with a better functional outcome
at 3 months (75). The recently finished Platelet Transfusion
in Cerebral Hemorrhage (PATCH) clinical trial (73) aimed
at determining whether platelet transfusion improves the risk
of hematoma growth and functional outcome in ICH patients
who were taking antiplatelet agents. The PATCH study demonstrated significant adverse events, higher mortality, and worst
long-term functional outcome in ICH patients who received
transfusion. On the basis of the results of this study, platelet
transfusion cannot be recommended as a standard procedure
in this specific patient population.
Other approaches to optimize antifibrinolytic therapy
have been used in combination with surgical evacuation.
In the “Intraoperative intravenous administration of rFVIIa
and hematoma volume after early surgery for spontaneous
intracerebral hemorrhage clinical trial,” the administration of
intravenous rFVIIa did not change the hematoma volume or
the functional outcome after ICH combined with early surgery.
Interestingly, the study showed that there were no meaningful
differences in the rates of deep venous thrombosis, myocardial
infarction, or cerebral ischemia (77). In the “International
Normalized Ratio (INR) Normalization in Coumadin Asso
ciated Intracerebral Hemorrhage phase III clinical study,”
investigators will test the hypothesis that the treatment for
coagulopathic ICH with PCC improves normalization of the
INR, hematoma growth, and clinical outcomes compared to
transfusions of fresh-frozen plasma (74).

TABLE 4 | Mechanisms implicated in the genesis and worsening of
perihematomal edema.
Early
<24 h

>72 h

24–72 h

• Cellular toxicity (white blood cells,
• Serum
platelets)
proteins
• Humoral toxicity [interleukin
• Glucose
(IL)-1, IL-6, intracellular adhesion
• Electrolytes
molecule, tumor necrosis factor
(Na, K)
alpha, prostaglandins, leukotrienes,
vascular endothelial growth factor,
complement]
• Coagulation cascade (thrombin,
fibrinogen, t-PA)
• Glutamate and amino acids
• Epinephrine?

• Blood degradation
products (Hgb, Fe,
biliverdin)
• Nitric oxide
• Free radicals
• Apoptosis
• Matrix
metalloproteinases
• Glutamate and
amino acids

With permission from Ref. (59).

edema), osmotically active serum proteins, and cytotoxic edema
from neuronal energy failure. Delayed PHE is produced by the
BBB disruption (vasogenic edema) and neuronal death (cytotoxic
edema) (20). Three intertwined neurotoxic cascades contribute
to the development of delayed PHE: inflammation, erythrocyte
lysis, and thrombin production (79). The combination of these
processes results in BBB disruption and death of brain parenchyma cells (Table 4).
Edema formation after ICH progresses through several
phases: a hyperacute phase involves transendothelial osmotic
pressure, clot retraction, and cytotoxic edema in the first several
hours; an acute phase in the first day involves the clotting cascade, thrombin production, and inflammatory activation; and a
third phase, beginning approximately 72 h post-ICH, involves
erythrocyte lysis and hemoglobin-induced neurotoxicity (80,
81). In general PHE progresses over 24 h, then remains relatively
constant for about 4 days and resolves over a period of several
weeks (6). Some studies suggest that a “penumbra” of progressive tissue damage and edema develop in the perihematomal
region (82). A 75% median increase in relative edema and 100%
median increase in absolute edema volume over the first 24 h
after ICH has been observed (83). In one study using SPECT,
perilesional CBF normalized from initially depressed levels
as PHE formed during the first 72-h post-ICH. The eventual
degree of PHE was associated with the volume of reperfused
tissue implicating reperfusion injury in the pathogenesis of PHE
formation (9). A significant heterogeneity in CBF can occur after
ICH with lower CBF (hypoperfusion) near the hematoma and
higher CBF (hyperperfusion) in healthy overlying subcortical
and cortical regions. The vasodilatory response of pial arteries
in the periphery of the injury zone may reflect a local inflammatory reaction.

PHE AFTER ICH
The secondary injury of ICH results is the formation of PHE,
which may contribute to an increase in peri-hematoma volume
by at least 75% (78). This progression of neuronal injury may
lead to increased ICP, herniation, neurological deficits, and
death. Enhanced models of hydrostatic and osmotic forces have
been recently formulated to explain PHE based on the unique
properties of the BBB. Early PHE is attributed to the transcapillary efflux of electrolytes and water from blood vessels (ionic

Frontiers in Neurology | www.frontiersin.org

Late

Hyperacute Phase

In this phase, PHE starts with the extravasation of serum into the
brain parenchyma and cellular dysfunction before BBB disruption.
Several early pathophysiologic events leading to early PHE are
related to the blood itself, which acts as a “neurotoxic” substance
(80, 81). During the first hours after ICH, clot retraction occurs
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with decreasing clot volumes and increasing PHE volume. Plasma
protein extravasation acts oncotically increasing the interstitial
osmotic pressure to induce rapid PHE development, extravascular coagulation, and fibrin deposition (80, 81). Experimental
evidence strongly supports the hypothesis that hyperacute PHE
is largely composed of peripherally exuded serum proteins after
clotting of the hematoma and consumption of plasma clotting
factors (83–85). Cytotoxic edema secondary to transcellular shifts
in Na+ and Cl− has also been shown to increase in the early
phases after ICH (85). Within hours, the ensuing cytotoxic edema
contributes to the transendothelial trans-BBB osmotic pressure
gradient. The mechanisms implicated in early cytotoxic edema
involve the extracellular accumulation of neurotoxins such as
glutamate, which is associated with further mitochondrial and
Na-ATP pump failure (86).

of glutamate in blood within the first 24 h of symptom onset
were associated with an exaggerated subacute pro-inflammatory
response and worst clinical outcome and increased volume of the
residual cavity after ICH (94). This supports the hypothesis that
excitotoxicity and inflammation have a role in PHE formation
and secondary neuronal death after ICH.
In addition to glutamate, high concentrations of IL-6, tumor
necrosis factor alpha (TNF-a), and intracellular adhesion
molecule-1 (ICAM-1) have been detected in the hypodense area
surrounding the hematoma. TNF-a was shown to increase BBB
permeability and cause WBC activation after its administration
in a piglet model of ICH (95). It may also has an effect on other
intracellular pathways such as G-protein-coupled activation of
phospholipases, which lead to the generation of free radicals
and an unhealthy redox state (96). Complex mechanisms in the
injured neuronal tissue activate both pro- and anti-inflammatory
mediators for at least 7 days after ICH. In parallel, transcript
expression of pro-inflammatory cytokines rise rapidly within 6 h
after the onset of ICH (97). In addition to these mechanisms, local
and systemic inflammatory mediators also enhance tissue damage by the activation of WBCS and generation of prostaglandins
and leukotrienes (59).
Although CNS tissues are normally immunologically privileged, BBB disruption may be expected to facilitate immune
cell entry into the peri-hemorrhagic tissue. Major inflammatory cells that are activated and accumulate within the brain
after ICH are primarily brain trafficked monocytes and resident
microglia (7, 98–105). Although pro-inflammatory cytokines
IL-1/IL-6/TNF-a can be released by many cell types, including
microglia, monocytes, and endothelial cells, their principal
sources in the brain are from activated microglia and brain
trafficked monocytes (105) The initial inflammatory response
after ICH is primarily orchestrated by the cytokines, TNF-a,
and IL-1b, which are upregulated within hours and increase
BBB permeability and allow entry of peripheral immune cells.
The cellular sources of these cytokines change during the 7-day
time course (106). When edema forms, activated microglia
contributes to the pathologic process through inflammatory
cells and mediators and cytokine release. TNF-a is present as
early as 1 day after ICH suggesting that synthesis and secretion
of cytokines may be an early response of microglia to ICH (7).
It has been demonstrated that microglia can also be maximally
activated at 7 and 10 days after ICH, which is the time frame
when the hematoma is being reabsorbed. The ICAM-1 is
inducible by tissue injury and other inflammatory cytokines
(107). The induction of ICAM-1 in neurons could promote
the attachment of WBCs to neurons inducing neuronal injury
through direct cell-to-cell interaction and the release of cytotoxic substances (7).
Neutrophils are also implicated in the development of PHE
via production of cytotoxic molecules such as pro-inflammatory
cytokines, reactive oxygen radical species, and MMPs (108). This
early inflammatory response has become an attractive therapeutic target. By inhibiting activation and migration of inflammatory
cells, research has shown that minocycline, a tetracycline derivative, may reduce microvessel loss, plasma protein extravasation,
and edema in addition to cytokine expression by reducing the

Acute Phase

Delayed edema formation may result from neuroinflammation and erythrocyte lysis, mediated by the local and systemic
upregulation of chemotaxins, the complement system activation, and the release of thrombin and hemoglobin by-products
(87). Inflammatory mediators also enhance early PHE after ICH
by activation of leukocytes and generation of chemokines and
chemotaxins via activation of the transcription factor NF-κB
(88). Both immunochemical and physical stress in the PHE area
lead to NF-κB activation with subsequent pattern recognition
by receptors such as toll-like receptors 2 and 4 and thrombin
engagement via protease-activated receptors (PARs). After
activation, the NF-κB leads to upregulation of target genes that
encode for cytotoxic cytokines, chemokines, and matrix metalloproteinases (MMPs), which are implicated in further BBB
disruption.
White blood cells (WBCs) and neutrophils infiltrate the
hemorrhagic brain within 4–5 h and may cause neuronal damage by producing reactive oxygen species and pro-inflammatory
proteases (89). Leukocytes die by apoptosis within 2 days after
entering the hemorrhagic brain damaging brain tissue through
microglia and macrophage activation (79). In this process, glutamate and other excitotoxic amino acids continue to accumulate
transiently in the extracellular fluid of the perihematomal region.
In one study, peak elevation in glutamate concentrations was
observed as early as 30 min post-ICH (90, 91).
Two hypotheses may explain the release of the neurotoxic
amino acids: ischemia and cellular trauma. In the setting of
ischemic injury, release of amino acids has been recorded and
cellular trauma to neurons has also been known to release intracellular stores of glutamate into the extravascular space. Damage
to astrocytes normally involved in the removal of glutamate may
also exacerbate the accumulation of extracellular glutamate and
other excitotoxic amino acids. Extraneuronal glutamate-based
neurotoxicity is the result of activation of the postsynaptic
N-methyl-d-aspartate receptor. The activation of this receptor
leads to cellular influx of Ca++ and Na+, leading to transcellular
ionic shift, cellular edema by flow of free water, and subsequent
neuronal death (92). Previous reports show that even a transient
exposure to glutamate can result in enhanced neurotoxicity
(93). One study for example showed that high concentrations
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upregulation of some pro-inflammatory cytokines such as TNF-a
and MMP-12 (109). This substance has been shown to reduce
specific cytokines (TNF-a and IL-1b) and MMPs implicated in
BBB damage (110).
The complement system is classically excluded from the
brain by the BBB, but it could enter in its activated form at the
time of ICH or through BBB disruption (111). Complementmediated brain injury is also assisted by the formation of the
membrane attack complex (MAC) and the pro-inflammatory
response that follows.
The MAC consists of the complement’s C5b–9 particles
assembled after its activation. Once activated, the MAC inserts
into the cell membrane forming a pore. The formation of MAC in
ICH models induces erythrocyte lysis, which has been implicated
in the generation of PHE (87). Not only does MAC cause cell
lysis but it also modulates other cellular pathways implicated in
the generation and release of cytokine, eicosanoid, and oxygen
radical species (112). Similarly, MAC insertion may also occur in
neurons and endothelial cells, causing neuronal death, cytotoxic
edema, and BBB leakage through damage of endothelial cells. In
animal models of ICH, therapeutic blockade of receptors for C3a
and C5a resulted in less neutrophilic infiltration and lower brain
water content compared with no treatment.
The MMPs are a family of proteolytic enzymes involved in the
reorganization of the extracellular matrix. Specifically, MMP-9
and MMP-2 degrade major components of the cellular wall’s
basal lamina and can disrupt the BBB (113). MMP-9 has been
linked to the pathophysiology of different neurological conditions such as multiple sclerosis and cerebral ischemia (114, 115).
One study showed that the levels of MMP-9 increased within the
first 24 h in patients with supratentorial ICH and that the concentrations of MMP-9 positively correlated with PHE volumes
in deep ICH (113).
Levels of MMPs and plasminogen activators are increased
16–24 h after in experimental collagenase-induced intracerebral hemorrhage models, suggesting that agents that block
MMPs may reduce the swelling after ICH (21). In this model,
treatment with an MMP inhibitor significantly reduced the
brain edema in sites distant from the primary lesion, suggesting that the inhibitor blocked vasogenic edema. Excessive
proteolysis is normally prevented by tissue inhibitors of MMPs,
but during the inflammatory process, the balance is disturbed
as their natural inhibitors (TIMPs) are destroyed, favoring
proteolysis. Astrocytes, endothelial cells, and microglia secrete
MMPs as inactive zymogens that must be activated by other
enzymes such as plasmin and free radicals (21). One study
investigated the temporal profile of MMPs and their natural
inhibitors after ICH and showed increased MMP-9 with PHE
and increased MMP-3 with mortality (5). MMP-3 is laminin
whose degradation leads to neuronal death. The main form of
cell death associated with ICH in the perihematomal region has
been shown to be apoptosis during the first days and necrosis
from inflammation after 5 days of symptom onset (90, 91). The
apoptotic pathway in ICH may involve nuclear factor kappa
beta, which is a transcription factor controlling MMPs (116).
TIMPs are now recognized as exerting both MMP inhibition
and antiapoptotic properties (5).
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Early edema formation is associated with both the activation of the coagulation cascade and the generation of thrombin (80, 81). Thrombin is a serine protease produced in the brain
immediately after ICH (117). It activates potentially harmful
pathways such as apoptosis, microglia activation, and glutamate
potentiation. Thrombin-induced brain edema results partly
from the disruption in the BBB and may be mediated by the
complement cascade. Thrombin is formed in the clot almost
immediately after an ICH, but the influx of prothrombin into the
brain tissue due to BBB disruption serves as a secondary source
(6). Intracerebral infusion of thrombin showed an increase in
complement C9 and deposition on neuronal membranes (118).
Thrombin-cleaved C3a-like fragments are chemotactic for
WBCs and can induce enzyme release for neutrophils (119).
Higher levels of TNF-a were seen after the infusion of thrombin
in one animal model of ICH (120).
The most direct effect of thrombin is its role in the coagulation
cascade with cleavage of fibrinogen to fibrin and other effects are
protein mediated. PARs regulate some of the pathological effects
of thrombin and are involved in CNS pathophysiology in some
animal studies (121). Thrombin is associated with permeability
change in the BBB leading to edema through chemotaxin and
MMP activation, as well as the release of vascular endothelial
growth factor (VEGF) from neurons through receptor activation
(122). VEGF increased vascular permeability and vasodilation via
nitric oxide induction and may serve as a potential fuel for free
radical generation (59). Thrombin at high concentrations also
kills neurons and astrocytes in vitro (123). It can be detrimental
at high concentration and protective at low concentrations (118).
To this end, thrombin-mediated brain injury has been identified
as a possible therapeutic target after ICH. Administration of a
thrombin inhibitor may effectively limit PHE formation and secondary neuronal damage (124). In the GUSTO-1 trial, the onset
of symptomatic ICH arising as a complication of thrombolysis
for acute myocardial infarction was ascertained and the potential
mechanisms studied. The psot hoc analysis of GUSTO-1 study
showed that there was minimal PHE when the patients received
thrombolytic therapy, suggesting that thrombin levels may have
been affected (125). Argatroban-mediated inhibition of thrombin
proved effective in reducing the degree of PHE in a rodent model
of ICH (126). The plasminogen activator inhibitor-1 (PAI-1)
protein levels increase in the rat brain after ICH or thrombin
infusion but brain levels of tPA remain unchanged (127). The
upregulation of PAI-1 after ICH implies that endogenous inhibitors of thrombin may limit brain injury and could be potential
future therapeutic agents. Although thrombin formation occurs
rapidly after ICH, it may remain within the clot and linked to
fibrin, which can in turn lead to delayed release of thrombin and
therefore delayed PHE (126).
Hyperglycemia can induce inflammatory reactions in ICH
leading to neuronal death (7, 128). Activated blood components
triggered by high glucose levels may induce increased inflammatory cytokine activity such TNF-a and IL-1, which exacerbates
BBB permeability causing vasogenic edema (129). Hyperglycemia
increases the secretion of IL-1b in cultured endothelial cells
and TNF-a in epithelial cells (130, 131). Free radical formation is increased with hyperglycemia-induced brain injury
7
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leading to increased BBB permeability and brain edema (132).
Hyperglycemia also induces bradykinin-mediated vasodilation
and inflammation. Bradykinin increases BBB permeability and
facilitates extravasation by dilation of arterial blood vessels (133).

a hydrogen peroxide intermediate factor (146). Iron reacts with
lipid hydroxyperoxides to produce free radicals. Deferoxamine, an
iron chelator, is routinely used to treat hemochromatosis caused
by iron toxicity. It also has been shown to reduce hemoglobininduced cerebral edema, indicating that iron is a key factor in
the pathway for delayed PHE formation after ICH. The degree
of secondary neuronal damage may be limited by changes in
iron-handling proteins. Specifically, an upregulation in the brain’s
iron-capturing protein ferritin may be neuroprotective.
Reactive oxygen species cause brain injury via many different
pathways. Deoxyribonucleic acid is vulnerable to oxidative stress
and markers have been observed at the perihematomal zone
demonstrating that oxidative DNA damage is involved in hemorrhagic brain injury (144). Iron can induce lipid peroxidation and
stimulate free radical formation, which in turn may cause DNA
damage (140). Although apoptotic DNA damage may occur from
erythrocyte-induced brain injury, non-apoptotic DNA damage
may play an important role because iron levels in the brain are
high after erythrocyte lysis (147). The degree of oxidative damage in tissues is limited by a number of free radical scavenging
systems. Intracerebral infusion of lysed RBCs causes marked
brain edema associated with increased protein carbonyl content
and DNA damage and thus reflecting oxidative stress (147). The
oxidative stress may be due to upregulation in HO with resultant
iron release.

Subacute Phase

Thrombin and the coagulation cascade play a major role in
acute edema formation following ICH as shown when thrombin
inhibitors markedly reduce edema formation (84). In contrast,
injection of whole red blood cells into brain fails to induce
edema formation by 24 h (19). This delayed RBC lysis may
be attributed to either activation of complement system and
formation of MAC (134) or depletion of intracellular energy
reserves (135). Hemoglobin has been shown to cause brain
injury through inhibition of sodium/potassium ATPase activity,
toxic radical generation, and lipid peroxidation (80, 81). In one
study, upon injection of packed RBCs, there was no edema
formation 24 h postinjection, but marked edema after 3 days.
This delayed edema is explained by RBC lysis and hemoglobin
release (80, 81). Hemoglobin release from erythrocyte lysis
increases during the first few days after an ICH (136). Studies
show that PHE formation after thrombin injection peaks at
1–2 days, whereas delayed edema formation from erythrocyte
lysis peaks at 3 days (80, 81).
The adverse effects of hemoglobin in models of ICH may
be due to the molecule itself or by its breakdown products.
Hemoglobin rapidly activates lipid peroxidation directly in the
first phase and then via iron, one of its breakdown by-products,
in the following phase (137). Haptoglobin may inhibit phase I,
whereas deferoxamine, an iron chelator, and transferrin, an ironbinding protein, can inhibit phase II. The heme from hemoglobin
may be broken down by heme oxygenase (HO) into iron (a potent
catalyst for lipid peroxidation), carbon monoxide, and biliverdin
(138). In turn, the enzyme biliverdin reductase catalyzes the
conversion of biliverdin to bilirubin. Both carbon monoxide and
iron can stimulate free radical formation leading to PHE. HO
is primarily increased in microglia cells around ICH, which are
also the most ferritin- and iron-positive cells (139). The intracortical injection of iron, causes focal epileptiform discharges
and more brain swelling (140). One study demonstrated that
hemoglobin also upregulated HO levels in the brain and that HO
inhibition by SnPP molecules reduced the classically observed
hemoglobin-induced brain swelling (141). HO overexpression
and reactive iron accumulation are also associated with oxygen
and free-radical species-related cytotoxicity (142). Early expression of HO may result from induction of other plasma proteins
and thrombin as well (143).
Intracerebral iron infusions have been shown to cause brain
edema and free radical formation leading to neuronal damage
(144). Erythrocyte lysis results in the accumulation of non-heme
iron molecules in the brain tissue starting at day 3 and reaching its
acme after about 7 days of ICH onset. The temporal relationship
between HO and non-heme iron levels indicates that an increase
in perihematomal HO levels may modulate home-based degradation and iron overload/toxicity in the brain with ICH (145).
Previous studies have shown that hemoglobin is toxic to spinal
neurons via an iron-dependent, oxidative mechanism involving
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CONCLUSION
Spontaneous forms of ICH account for 10–20% of all strokes
annually in the United States and is associated with the highest
all-time morbidity and mortality (148). Among the factors related
to poor prognosis after ICH are the hematoma size, growth, and
PHE. To determine therapeutic targets, it is important to evaluate
the mechanisms of each phase. Information of the pathophysiologic mechanisms of injury have been identified as primary and
secondary.
Hematoma growth in the setting of ICH has a multifactorial etiology with contributing factors such as increased local
tissue pressure, a fibrinolytic effect, plasma protease induction,
and secondary inflammation. Reduction in hematoma size and
growth will likely be important futuristic strategies to improve
survival and outcome after ICH. This depends heavily on both
BP management and hemostasis. Seven clinical trials have evaluated the role of intensive BP reduction after ICH and ultimately
concluded that intensive lowering of BP (SBP < 140 mmHg)
provides no significant improvement in outcome compared to
the standard goal of SBP < 180 mmHg. Medical treatment for
hemostasis varies if the patient was taking an anticoagulant or
had an inherent coagulopathy. However, in spontaneous ICH, not
related to anticoagulation, rFVIIa has been evaluated as a means to
reduce hematoma growth and PHE formation. Although a phase
II randomized clinical trial showed that treatment with rFVIIa
reduced hematoma growth and improved clinical outcome after
ICH, a conclusive phase III clinical trial failed to demonstrate any
significant benefit.
The primary injury of hematoma formation and clot retraction occurs followed by secondary injury with BBB disruption
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